Bruceantin (51) could efficiently suppress tumor growth and metastasis of castration-resistant prostate cancer cells and overcome resistance caused by aberrant full-length androgen receptor (AR-FL)/AR-V7 signaling via targeting HSP90 expression (Moon et al., 2021). This evidence concerns the gene AR and Familial prostate cancer.